RT Journal Article
T1 Analgesic efficacy of zoledronic acid and its effect on functional status of  prostate cancer patients with metastasis
A1 Gálvez, Rafael
A1 Ribera, Victoria
A1 González-Escalada, José Ramón
A1 Souto, Alicia
A1 Cánovas, María Luz
A1 Castro, Andrés
A1 Herrero, Begoña
A1 Maqueda, María de los Ángeles
A1 Castilforte, Matilde
A1 Marco-Martínez, José Javier
A1 Pérez, Concepción
A1 Vicente-Fatela, Lorenza
A1 Nieto, Consuelo
A1 Orduña, Maria José
A1 Padrol, Anna
A1 Reig, Enrique
A1 Carballido, Joaquín
A1 Cózar, José Manuel
K1 Neoplasias de la Próstata
K1 Metástasis de la Neoplasia
K1 Dolor
K1 Difosfonatos
K1 Estudios Multicéntricos como Asunto
K1 Masculino
K1 Bone metastasis
K1 Pain
K1 Prostate cancer
K1 Zoledronic acid
AB Objectives: A multi-centered observational study evaluated the efficacy of zoledronic acid for improving pain and mobility, and preventing skeletal-related events (SRE) (fracture, spinal compression, pain-relieving radiotherapy), in patients with prostate cancer and bone metastasis.Materials and Methods: Males (n = 218) with prostate cancer and bone metastasis undergoing oncologic therapy received zoledronic acid (4 mg iv/month) for 6 months. Parameters evaluatedwere: 1) pain and movement after 2 consecutive doses; 2) quality of life; 3) SRE incidence and time-to-appearance. Medication tolerance and treatment satisfaction were assessed usinga questionnaire.Results: A total of 170 that matched all the inclusion criteria (78%) out of 218 were evaluable for efficacy. There was a measurable statistically significant reduction in pain at rest and on movement as well as an improvement in the quality of life compared with baseline. Best results were obtained with early treatment. Overall incidence of bone events was 11.2%. Ofthe 212 patients (97.2%) evaluable for safety, 16% suffered adverse events and 66% expressed satisfaction with the treatmentDiscussion: Zoledronic acid is effective for reducing pain, improving mobility, and increasing the quality of life in patients with prostate cancer with bone metastasis. Its easy administration and good tolerability make zoledronic acid one of the principal therapeutic tools in the managementof patients with pain associated with bone metastasis from prostate cancer.
PB Dove Medical Press
SN 1177-889X (Online)
YR 2008
FD 2008-08
LK http://hdl.handle.net/10668/652
UL http://hdl.handle.net/10668/652
LA es
NO Galvez R, Ribera V, González-Escalada JR, Souto A, Cánovas ML, Castro A et al. Analgesic efficacy of zoledronic acid and its effect on functional status of  prostate cancer patients with metastasis.Patient Prefer Adherence. 2008 Feb 2;2:215-24.
DS RISalud
RD Apr 12, 2025